The ENO3 antibody targets enolase 3 (ENO3), a glycolytic enzyme encoded by the *ENO3* gene. ENO3. also known as β-enolase, is a muscle-specific isoform of the enolase family, which catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate during glycolysis. It is predominantly expressed in skeletal muscle and plays a critical role in energy metabolism, particularly under high-energy-demand conditions. ENO3's tissue specificity makes it a biomarker for studying skeletal muscle function and related pathologies.
ENO3 antibodies are widely used in research to investigate muscle diseases, such as muscular dystrophies, myopathies, or metabolic disorders linked to glycolytic dysfunction. They also aid in diagnosing certain cancers, as aberrant ENO3 expression has been observed in tumors like rhabdomyosarcoma. Additionally, these antibodies are valuable in immunohistochemistry (IHC), western blotting, and immunofluorescence (IF) to localize and quantify ENO3 in tissue samples or cell lines.
Recent studies highlight ENO3's potential role beyond glycolysis, including interactions with hypoxic responses and extracellular signaling, expanding its relevance in cancer biology and muscle regeneration research. Commercial ENO3 antibodies are typically raised against specific epitopes, with validation in muscle-derived samples ensuring specificity. Understanding ENO3's regulation and function through antibody-based assays contributes to therapeutic target discovery and mechanistic insights into muscle-related and metabolic diseases.